arrow
R

Richard D. Carvajal

northwell health
H指数:74
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Computationally Assisted Patient Finding for Navigation to Optimize Pancreatic Cancer Care Access

计算辅助的患者查找与导航,以优化胰腺癌护理的可及性

2026-02-260
OA
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients

联合局部疗法可延长tebentafusp在转移性眼葡萄膜黑色素瘤患者中的临床获益

2025-10-010
OAAI
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504

更正:Shoushtari等人。一项关于Sotrastaurin(一种PKC抑制剂)和Alpelisib(一种PI3Kα抑制剂)在转移性眼黑色素瘤患者中的Phase Ib研究。Cancers 2021, 13, 5504。

2025-09-230
OAAI
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

接受T细胞受体-CD3双特异性抗体tebentafusp治疗期间肿瘤免疫景观的演变

2025-04-010
OAAI
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
2025-01-270
OAAI
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
2025-01-010
OAAI
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023
2024-10-090
OA
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion
2024-05-211
PRE
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
2023-12-208
OA
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Tebentafusp治疗转移性葡萄膜黑色素瘤的三年总生存率

2023-12-1449
OA
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)
2023-10-072
OA
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2023-04-169
OA